374 related articles for article (PubMed ID: 28511816)
1. Mechanisms of Immune Tolerance in Leukemia and Lymphoma.
Curran EK; Godfrey J; Kline J
Trends Immunol; 2017 Jul; 38(7):513-525. PubMed ID: 28511816
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.
Seliger B
HLA; 2016 Nov; 88(5):213-220. PubMed ID: 27659281
[TBL] [Abstract][Full Text] [Related]
3. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
4. Programmed death-1 checkpoint blockade in acute myeloid leukemia.
Sehgal A; Whiteside TL; Boyiadzis M
Expert Opin Biol Ther; 2015; 15(8):1191-203. PubMed ID: 26036819
[TBL] [Abstract][Full Text] [Related]
5. PD-L1.
Kythreotou A; Siddique A; Mauri FA; Bower M; Pinato DJ
J Clin Pathol; 2018 Mar; 71(3):189-194. PubMed ID: 29097600
[TBL] [Abstract][Full Text] [Related]
6. Coinhibitory Pathways in Immunotherapy for Cancer.
Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
[TBL] [Abstract][Full Text] [Related]
7. Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.
Falchi L
Curr Hematol Malig Rep; 2017 Oct; 12(5):484-494. PubMed ID: 28822058
[TBL] [Abstract][Full Text] [Related]
8. [Immune-checkpoint and hemopathies].
Burroni B; Broudin C; Damotte D; Laurent C
Ann Pathol; 2017 Feb; 37(1):101-110. PubMed ID: 28161001
[TBL] [Abstract][Full Text] [Related]
9. Part I: Checkpoint inhibitors in cancer therapy.
Daud AI
Immunotherapy; 2016 Jun; 8(6):675-6. PubMed ID: 27197535
[No Abstract] [Full Text] [Related]
10. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptors in lymphoid malignancies: double-edged sword.
Harsini S; Beigy M; Akhavan-Sabbagh M; Rezaei N
Crit Rev Oncol Hematol; 2014 Feb; 89(2):262-83. PubMed ID: 24051205
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase.
Aguilera TA; Giaccia AJ
Clin Cancer Res; 2017 Jun; 23(12):2928-2933. PubMed ID: 28289089
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.
Nagorsen D; Bargou R; Ruttinger D; Kufer P; Baeuerle PA; Zugmaier G
Leuk Lymphoma; 2009 Jun; 50(6):886-91. PubMed ID: 19455460
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint blockade in lymphoid malignancies.
Thanarajasingam G; Thanarajasingam U; Ansell SM
FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
[TBL] [Abstract][Full Text] [Related]
15. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Immunological Synapses Driven by Leukemic Antigen-Presenting Cells.
Lucas FM; Gribben JG
Methods Mol Biol; 2017; 1584():533-544. PubMed ID: 28255724
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy.
Verhoeven D; Stoppelenburg AJ; Meyer-Wentrup F; Boes M
Clin Immunol; 2018 May; 190():22-31. PubMed ID: 29499421
[TBL] [Abstract][Full Text] [Related]
18. T Cells Deficient in Diacylglycerol Kinase ζ Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia.
Jing W; Gershan JA; Holzhauer S; Weber J; Palen K; McOlash L; Pulakanti K; Wesley E; Rao S; Johnson BD; Riese MJ
Cancer Res; 2017 Oct; 77(20):5676-5686. PubMed ID: 28916658
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.
Rivière I; Sadelain M
Mol Ther; 2017 May; 25(5):1117-1124. PubMed ID: 28456379
[TBL] [Abstract][Full Text] [Related]
20. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.
Luo M; Fu L
Oncotarget; 2016 May; 7(20):29794-803. PubMed ID: 26919108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]